Published in final edited form as:

ACS Chem Biol. 2011 June 17; 6(6): 636–647. doi:10.1021/cb2000346.

Small Molecule Inhibition of the TNF Family Cytokine CD40 Ligand Through a Subunit Fracture Mechanism

Laura F. Silvian^{1,*}, Jessica E. Friedman¹, Kathy Strauch¹, Teresa G. Cachero^{1,4}, Eric S. Day¹, Fang Qian¹, Brian Cunningham², Amy Fung^{2,5}, Lihong Sun¹, Gerald W. Shipp^{7,8}, Lihe Su¹, Zhongli Zheng^{1,6}, Gnanasambandam Kumaravel¹, and Adrian Whitty^{3,*}

¹Department of Drug Discovery, Biogen Idec, 12 Cambridge Center, Cambridge, Massachusetts 02142.

²Sunesis Pharmaceuticals, Incorporated, 341 Oyster Point Boulevard, South San Francisco, CA 94080.

³Boston University, Department of Chemistry, Metcalf Center for Science and Engineering, 590 Commonwealth Ave, Boston, MA 02215.

⁷Neogenesis Pharmaceuticals Inc., 840 Memorial Dr., Cambridge, MA 02139

Abstract

BIO8898 is one of several synthetic organic molecules that have recently been reported to inhibit receptor binding and function of the constitutively trimeric tumor necrosis factor (TNF) family cytokine CD40 ligand (CD40L, a.k.a. CD154). Small molecule inhibitors of protein-protein interfaces are relatively rare, and their discovery is often very challenging, therefore to understand how BIO8898 achieves this feat we characterized its mechanism of action using biochemical assays and X-ray crystallography. BIO8898 inhibited soluble CD40L binding to CD40-Ig with a potency of IC₅₀ ~25 μ M, and inhibited CD40L-dependent cell apoptosis in a cellular assay. A co-crystal structure of BIO8898 with CD40L revealed that one inhibitor molecule binds per protein trimer. Surprisingly, the compound binds not at the surface of the protein, but by intercalating deeply between two subunits of the homotrimeric cytokine, disrupting a constitutive protein-protein interface and breaking the protein's three-fold symmetry. The compound forms several hydrogen bonds with the protein, within an otherwise hydrophobic binding pocket. In addition to the translational splitting of the trimer, binding of BIO8898 was accompanied by additional local and longer-range conformational perturbations of the protein, both in the core and in a surface loop. Binding of BIO8898 is reversible, and the resulting complex is stable and does not lead to detectable dissociation of the protein trimer. Our results suggest that a set of core aromatic residues that are conserved across a subset of TNF family cytokines might represent a generic hot-spot for the induced-fit binding of trimer-disrupting small molecules.

Obtaining small molecule (i.e. synthetic organic) inhibitors against protein-protein interactions (PPI) is a major current challenge in chemical biology and drug discovery (1-4).

*To whom correspondence should be addressed: whitty@bu.edu, laura.silvian@biogenidec.com.

⁴Current address: Vertex Pharmaceuticals Inc., 130 Waverly St., Cambridge, MA 02139.

⁵Current address: Roche Pharmaceuticals, Palo Alto, CA 94304

⁶Current address: WinerGen Technologies Inc, Ltd., Biotech Center, Gaoxin district, Weifang.

⁸Current address: Merck Research Laboratories, 33 Avenue Louis Pasteur, Boston, MA 02115.

Accession codes. The structure has been deposited with pdb code 3LKJ.

Conflict of Interest Disclosure: The authors with the exception of BC and AF are at present or were at one time Biogen Idec employees and owned or still own Biogen Idec stock.

Supporting Information Available: This material is available free of charge *via* the Internet.

Despite many attempts involving a wide range of PPI targets, if special cases such as integrins, proteinases and GPCRs are excluded then only a relatively small number of PPI inhibitors have been reported and, with the exception of some complex natural products (5), in only a handful of cases has a synthetic inhibitor of a classical PPI interface progressed as far as clinical trials (6-8). Improving this historically low success rate would potentially render tractable a large number of biologically compelling PPI targets. Because relatively few PPI inhibitors have been reported, each new example adds to our knowledge of how ligand binding and inhibition can be achieved in such systems. This is particularly true for inhibitors of constitutive – rather than transient – PPI, which present a distinct challenge (9, 10) and for which few well-characterized inhibitors exist (11, 12).

The TNF family cytokine CD40 Ligand (CD40L) is a compelling target for inhibition by a small molecule. This is because, although it is located on the external surface of the cell, it has proven intractable to targeting by protein therapeutics for reasons that a small molecule inhibitor might circumvent. CD40L is expressed on activated T cells, B cells and a number of other cell types, and signals through interaction with CD40, a 45 kDa type I membrane receptor located primarily on B-cells, monocytes and macrophages (13). A number of antibodies that block the CD40L/CD40 interaction, such as hu5c8, have reached clinical trials in autoimmune diseases including Lupus Nephritis (14), allotransplant rejection (15, 16) and atherosclerosis (17). When present in stoichiometric excess, the hu5c8 Fab fragment binds at three identical symmetry-related epitopes on the CD40L trimer (18). The antibody binds at a site that overlaps the expected CD40 binding site at each of the three subunit interfaces of CD40L (19). Clinical trials with these anti-CD40L antibodies on autoimmune patients have been halted, however, due to thromboembolic complications (20). The cause of these adverse events is not fully known, but has been proposed to involve Fc cross-linking or effector functions of the antibodies (21). If so, this undesirable activity could be circumvented by a small molecule inhibitor, potentially resulting in a more favorable safety profile.

Several small molecule inhibitors of the CD40L/CD40 interaction have been reported recently. Suramin, a polyaromatic bisnaphthylamine trisulfonic acid that shows immunosuppressive activity (22), was first reported to inhibit TNF α /TNFR interactions (23, 24). It was shown by gel filtration and by biochemical measurements to function by disrupting the trimeric structure of TNF α , though no structural information exists to show how trimer disruption is achieved. More recently, Suramin has been shown to also inhibit CD40L binding to CD40, and indeed in biochemical binding assays and B-cell proliferation assays does so with 30-fold higher potency compared to its inhibition of TNF α /TNFR (25). Subsequently, a variety of other polyaromatic compounds have been reported to inhibit the CD40L/CD40 interaction with micromolar affinities (26, 27), including the food-colorant erythrosine which is a promiscuous inhibitor of protein-protein interaction interfaces (28). This suggests that this interface is druggable by small molecule inhibitors. Understanding whether these compounds, or smaller fragments derived from them, might represent viable starting points for drug discovery against CD40L, and if so how they might be optimized to improve their affinity and selectivity, would be greatly aided by knowledge of the mechanism of action of these inhibitors on CD40L, which has not previously been determined.

We report here the characterization of a small molecule inhibitor of CD40L, designated BIO8898 (29), that exemplifies a novel mode of action for a PPI inhibitor. A high-resolution co-crystal structure of the inhibitor-target complex shows that BIO8898 acts by disrupting the structure of the constitutively trimeric CD40L molecule. The compound intercalates between two subunits, accessing the core of the trimer and disrupting its native, three-fold symmetry. This mechanism of action of BIO8898 is reminiscent of the trimer disruption

mechanism that was recently reported for the trimeric cytokine TNF α (12), though there are also important differences. Our results suggest that trimer disruption represents a generic mechanism for inhibition of TNF family cytokines – and potentially also other constitutively oligomeric proteins – by small molecule inhibitors. Indeed, based on the topology of the CD40L/BIO8898 complex we propose that some constitutive PPI complexes might, counter-intuitively, be easier to inhibit with a small molecule than are lower affinity, transient PPI interfaces.

RESULTS AND DISCUSSION

Biochemical Characterization

BIO8898 (Figure 1A) was reported several years ago as a discovery resulting from screening a compound library for the ability to bind to CD40L (29), as detected by mass spectrometry after rapid separation from unbound library members by gel filtration (30). Because small molecule inhibitors of PPI targets such as CD40L are rare and potentially of interest as drug leads, we further characterized the activity of BIO8898 to establish its mechanism of action.

The compound, synthesized as described in the Methods (Supplementary Figure S1), inhibits CD40L activity in assays measuring receptor binding and also functional activity. Figure 1B shows that BIO8898 inhibits the binding of myc-tagged soluble CD40L (mycCD40L) to an assay plate coated with a CD40-Ig fusion protein comprising the extracellular domain of CD40 fused to the hinge, CH2 and CH3 domains of human IgG1. Binding of mycCD40L to the plate was measured by Dissociation Enhanced Lanthanide Fluorescence Immunoassay (DELFI) (31), using a europium-labeled anti-myc antibody as detection reagent. In this assay, BIO8898 inhibited CD40L binding with a concentration giving 50% inhibition (IC₅₀) of ~25 μ M. The activity of BIO8898 in a cellular context was also evaluated, using a baby hamster kidney (BHK) cell line stably transfected with a chimeric receptor comprising the extracellular domain of CD40 fused to the transmembrane and cytoplasmic domains of the structurally related TNF family receptor TNFRp75. In this assay, ligation of CD40 by CD40L causes cell death through apoptosis mediated by the TNFRp75 death domain (32). Cell viability after two days was measured by MTT staining. In viable cells MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) is enzymatically reduced by the mitochondrial respiration pathway, generating a dark blue formazan product that can be quantified as a measure of the number of living cells (33). Figure 1C shows that BIO8898 inhibits CD40L-induced apoptosis in this assay in a dose-dependent manner. The dose-response in the assay does not reach saturation because the highest dose at which BIO8898 could be tested (111 M) was limited by the compound's solubility at the very low DMSO levels tolerated by this assay. Nevertheless, the potency observed in the apoptosis assay is within ~3-fold of the 25 μ M IC₅₀ seen Figure 2B, which is entirely in keeping with the somewhat lower potency that is often observed in cellular assays versus biochemical inhibition assays. This result establishes that BIO8898 inhibits the interaction of CD40L with CD40 in a cellular context, and thus its activity in Figure 2B is not an artifact of the CD40-Ig construct or the assay format used for the inhibition assay.

The biochemical activities of compounds with low potencies such those observed for BIO8898 in Figures 2B and 2C can result from a variety of assay artifacts including promiscuous aggregation-based inhibition (34, 35). We therefore attempted to co-crystallize the compound with CD40L to establish whether it possessed a distinct and robust binding mode that would validate it as a *bona fide* 'hit' and, if so, to derive clues concerning how binding occurs in this case and how the potency of the compound might be improved. To maximize site occupancy by the weak-binding BIO8898, CD40L (100 μ M) was crystallized with 1 mM compound, representing a large excess over both the protein concentration and the K_D for their interaction (presumed to be less than or equal to the IC₅₀ value of 25 μ M

from Figure 1B). The resulting crystal diffracted to a resolution of 2.5 Å and the structure was solved by molecular replacement using native CD40L as a search model, followed by domain-independent rigid body refinement.

Structure of the Complex

The structure revealed the surprising result that, although native CD40L is constitutively homotrimeric (Figure 2B) and contains three identical receptor binding sites (36), each CD40L trimer binds only a single molecule of BIO8898. Clear difference density was observed at 2.5 sigma levels at 2.5 Å resolution. The compound was placed into density and its orientation was unambiguous in the complex despite its quasi-symmetrical four-armed structure. An unbiased sigma-A weighted omit map in which refinement was performed in the absence of compound indicates that the compound binds in only one orientation (Figure 2A). Most surprisingly, BIO8898 binds not to the surface of the protein, but rather intercalates between two subunits in the CD40L trimer, accessing the core of the protein and disrupting its native 3-fold symmetry (Figures 2C, D, E). The small molecule binds between the hydrophobic surfaces of the interface between two subunits, designated A and C, with one 2-(N-pyrrolidinomethyl)pyrrolidine substituent directed towards the solvent (Arm 1) while the second projects towards the interior core of the trimer (Arm 2; see Figs 1A, 2F). The 2-cyclohexyl-2-aminoacetic acid substituent (Arm 3) points towards solvent, but is covered by the CD40L AA' loop, comprising residues Tyr145, Tyr146 and Met148 of monomer C, protecting the hydrophobic surface of this substituent from exposure to solvent. The carboxylate group on Arm 3 interacts with the protein through direct and water-mediated hydrogen bonds with the backbone amides, as described below. The remaining, 2-aminomethylbiphenyl substituent (Arm 4) of the compound projects deep into the CD40L trimeric core. The position occupied by Arm 4 in the core of the protein makes it impossible for more than one compound to bind per trimer due to steric occlusion. Based on calculations of interface buried surface area using ProtolP v. 1.0 (37), the buried protein surface area of CD40L contacting BIO8898 totals 485 Å², which is approximately one quarter of the total surface area that is buried at the interface between two subunits in unbound CD40L (974 Å² per subunit = 1950 Å² buried surface area).

The induced cleft that forms the binding site for BIO8898 is largely hydrophobic, and is lined by the side chains of residues L168, Y170, V228, E230, L259 and L261 of Chain A, Y170, Y172, A173, Q174, H224 and L225 of Chain B, and A123, H125, Y145, Y146, Y170, Y172, H224, S255, Leu259 and L261 of Chain C. The contact area between BIO8898 and the protein is 81% hydrophobic, 11% neutral, and 6% polar. The bipyridyl core of the inhibitor appears to π -stack with the Tyr172 side-chain of subunit C, and the biphenyl group of Arm 4 makes a perpendicular π - π interaction with Tyr172 from subunit B. While the compound is mainly bound by hydrophobic interactions, it also makes several hydrogen bonds (Figure 3A), all with subunit C. The inhibitor carboxylate group makes direct hydrogen bonds with the backbone amide of Tyr145 and water-mediated hydrogen-bonds to the His125 and Tyr146 backbone amides, and the amide NH of the biphenyl arm donates a hydrogen bond to the phenol hydroxyl of Tyr170 while the amide carbonyl of this arm makes a water-mediated hydrogen bond to Ser255 (Figure 3A). These hydrogen bonds presumably help stabilize a specific orientation of the molecule within what is otherwise a highly non-polar environment.

At least six water molecules can also be identified in the induced binding site in the complex (Figure 3A). These waters mediate protein-ligand binding and fill cavities that the inhibitor does not occupy. Two of these waters (#79 and #56) are in good locations for their binding sites to be exploited by modification of the inhibitor, as they are hydrogen bonded to the carboxylate and may allow for easy library-based chemical modification to replace the carboxylate with larger, polar functional groups. Other waters (#64, 51 & 80) occupy

additional cavities in the binding site, and particularly the central cavity. None of these buried water molecules are observed in the native CD40L trimer. Overall, the observed pharmacophore can be considered as one hydrogen bond donor and three acceptors on BIO8898 interacting with multiple hydrogen bond donors and acceptors on the protein, buried in an otherwise hydrophobic contact interface.

A phenomenon that has been invoked as an important feature of the binding of small molecule ligands to PPI targets is the ability of the protein to adapt its shape to better accommodate the organic ligand (4, 38). Comparing the structure of the bound CD40L molecule with that of the native protein provides insight into the extent to which structural adaptivity contributes to ligand binding in this system. While the largest structural changes are due to the translational split between the A and C subunits (Figs 2C, 3B), there are also conformational changes in both side-chain and main-chain atoms to accommodate specific portions of the inhibitor. In particular, residues His224 and Tyr170 from all three subunits, which in the native trimer come together to form a relatively close-packed core (Figure 3C), are displaced in the BIO8898-bound form (Figure 3D) such that the Tyr170 residues from chains A and C separate laterally to form a cleft that accommodates the proximal regions of Arms 2 and 4 and their connecting atoms. At the same time the three tyrosines separate axially from the three His224 side-chains, which also rotate slightly, to form a deep lateral cavity that snugly accepts the projecting biphenyl group of Arm 4. Similarly, residues Leu259 from subunits A and C move apart to accommodate arm 2 of the inhibitor. Finally, the AA' loop of subunit C, which includes Tyr145-Tyr146, reorganizes to form a flap that folds over Arms 1 and 3 of the inhibitor and partially shields them from solvent (Figure 3E). Thus, induction of the inhibitor binding site involves substantial local, intermediate-range and global changes in protein structure, of which the creation of a cleft between subunits A and C is just one part.

Mechanism of Inhibition

The mode of inhibition observed for BIO8898 can be compared to the recently reported inhibition of the homologous trimeric cytokine TNF α by the small molecule SP307 (Figure 4A) (12). Like BIO8898, SP307 disrupts the trimeric structure of a TNF family cytokine and binds to a newly exposed site in the core of the protein. However, SP307 disrupted the structure of the TNF α trimer to the extent that one protein subunit was fully ejected, leading to a complex in which the small molecule bound to the exposed core of an unprecedented dimeric form of the protein. Intriguingly, when the BIO8898/CD40L and SP307/TNF α complexes are superimposed, the binding site for SP307 in TNF α overlaps with the site in CD40L that accommodates Arm 4 of BIO8898 (Figure 4B). Moreover, in both cases inhibitor binding is dominated by interactions with aromatic residues on the protein. BIO8898/CD40L interacts with Y145 and Y146 (subunit C), Y170 (subunit A, B and C), Y172 (subunits B, C), H224 (subunits A, B and C), and L261 (subunit A) (Figure 4C). In TNF α the binding site for SP307 is lined primarily by the side-chains of six tyrosine residues, at positions 59, 115 and 119 on each of the two remaining protein subunits. Residues Leu57 and Tyr151 also make up part of the binding pocket (Figure 4C). For SP307 binding to dimeric TNF α the compound buries only a total of 98 Å² for this micromolar affinity interaction; the interface is composed of 74% nonpolar, 14% neutral and 9% polar atoms, similar to the percentages observed for BIO8898 binding to CD40L, but unlike BIO8898 SP307 makes no hydrogen bonding interactions with the protein.

A preponderance of aromatic residues in the interface region is common to many TNF family cytokines (Figure 4D). The extensive similarities in both the binding locations and in the types of interactions formed in the two complexes that have so far been observed suggest that this region of the core of TNF family trimers might represent a hot-spot for the binding

of small molecules, potentially leading to conformational distortion or complete disruption of the trimeric ligand.

To test whether the inhibitory activity observed with BIO8898 results from formation of the one inhibitor per trimer complex seen crystallographically, or alternatively whether in solution the binding of BIO8898 with CD40L causes ejection of one or more subunits as is the case with SP307 inhibition of TNF α , we directly tested the ability of BIO8898 to dissociate the CD40L trimer in solution using an assay analogous to that we used previously to characterize the dissociation of TNF α by SP307 (12). Briefly, singly biotinylated CD40L, captured on a neutravidin-coated assay plate, was incubated with compound at various concentrations. The ability of the captured CD40L to bind CD40-Ig was measured either with or without a prior wash step to remove any dissociated CD40L subunits. If trimer dissociation occurs the dissociated subunits would be expected to recombine with each other in solution and then become lost upon washing, resulting in a loss of active CD40L from the assay plate. Figure 5A shows that incubation of the singly biotinylated CD40L with 167 or 500 M compound inhibited CD40-Ig binding as expected, but if the plate was washed before CD40-Ig addition then essentially no inhibition was observed. This result shows that inhibition by BIO8898 is reversible, and does not cause dissociation of CD40L subunits. These results contrast with those from a similar assay with SP307 using singly-biotinylated TNF α , in which this known trimer disruptor showed inhibition even when a wash step was included prior to addition of the soluble receptor, indicating that the compound caused dissociation of nonbiotinylated TNF α subunits from the assay plate.

BIO8898 inhibits both receptor binding and functional activity of CD40L, indicating that formation of the BIO8898/CD40L complex renders the protein inactive. Of the three identical binding sites for CD40 that exist in native CD40L, only one is extensively disrupted in the BIO8898/CD40L complex. Intercalation of the inhibitor between CD40L subunits A and C pushes them apart by several angstroms, severely distorting the structure at that site. Moreover, portions of the inhibitor project into the solvent in a position that would likely occlude receptor binding. In addition, the inhibitor makes extensive interactions with the AA' loop, which has been shown to be important for receptor binding (18, 39, 40). The data in Figure 1B show that BIO8898 reduces the ability of CD40L to bind to CD40-Ig. To fully interpret how the structural distortion of CD40L in the complex with BIO8898 affects receptor binding, however, it is necessary to know whether the interaction of CD40L with CD40-Ig in our binding assay minimally requires occupancy of one, two or three of the receptor binding sites on CD40L. If occupancy of only one or two binding sites per CD40L trimer is sufficient to achieve binding, then the inhibition observed in Figure 1B cannot be explained by disruption of just one of the trimer interfaces in the BIO8898/CD40L complex. Instead it would imply that the structural deformation of the CD40L trimer that occurs upon BIO8898 binding is sufficient to disrupt two or three of the receptor binding sites. To distinguish these possibilities we characterized the binding of CD40L to CD40-Ig, and also to a soluble monomeric form of CD40 extracellular domain (sCD40), by surface plasmon resonance (Biacore), using an initial rates ligand-receptor titration method that we have described previously (41). Briefly, we incubated CD40L with CD40-Ig or sCD40 at several different molar ratios for sufficient time for binding to come to equilibrium. The equilibrium ratio of bound versus free CD40L at each molar ratio of CD40L with CD40-Ig or sCD40 was then measured by analyzing each equilibrated solution by Biacore, using the initial rate of CD40L binding to the CD40-Ig on the chip, under mass transport-limited conditions (42), as a measure of free CD40L. This initial rates titration method has been shown previously to provide an accurate measure of the binding affinity – and sometimes also the stoichiometry – for the interaction of unlabeled proteins in solution (41).

The results show that the binding of soluble CD40L to CD40-Ig in solution fits a single site binding model, giving an apparent binding affinity of 7.6 ± 2.1 nM ($n = 13$) (Figure 5B). In contrast, CD40L binds sCD40 approximately 1000-fold less strongly ($K_D \sim 13$ μ M ($n = 2$)) (Figure 5C). To our knowledge this is the first quantitative measurement of the binding affinity of monomeric CD40 for a single binding site on CD40L, but is fully consistent with previous reports that a bivalent or multivalent form of CD40 is required for strong binding to CD40L (43-46). These results indicate that high affinity binding to CD40L requires cooperative binding of both CD40 “arms” of CD40-Ig to two adjacent binding sites on the CD40L trimer. The very weak binding observed for occupancy of a single CD40L binding site is insufficient to give a measurable signal under the conditions of the CD40L/CD40-Ig ELISA shown in Figure 1B, but occupancy of two binding sites by a single CD40-Ig molecule appears sufficient for strong binding. Therefore, the result that BIO8898 inhibits the binding of CD40L to CD40-Ig (Figure 1B) suggests that BIO8898 likely disrupts more than one receptor binding site on CD40L. Superposition of the complex structure with that of native CD40L by overlapping subunit B supports the existence of considerable distortion of the other two receptor binding sites (AB interface and BC interface), suggesting that the inhibitory effect of BIO8898 in part involves allosteric disruption of receptor binding sites adjacent to the site occupied by the compound (Supplementary Figure S3).

Comparison of the structural and inhibition data for BIO8898 with CD40L and SP307 with TNF α leads us to speculate that these two cases might represent variations on a common inhibition mechanism (Figure 4E). In both cases, the initial step is binding of the inhibitor to the trimeric cytokine to form a complex *CI* (Figure 4E) in which the native subunit interactions are significantly disrupted (12). In the case of SP307 with TNF α this disruption was sufficient to cause ejection of a subunit, whereas for BIO8898 with CD40L the trimer remains intact but is structurally distorted to the extent that it can no longer bind strongly to CD40. In the case of SP307 with TNF α the initial 1:1 complex *CI* was not structurally characterized, but its existence was inferred from kinetic and biophysical data (12). It is highly likely that the weakening of the inter-subunit interactions in TNF α upon initial binding of SP307 is due to the intercalation of this inhibitor between two subunits, involving formation of an intermediate complex with an intercalated structure analogous to the stable complex observed for CD40L with BIO8898. The structure of BIO8898 with CD40L therefore potentially provides significant new insight into the first step of this trimer disruption mechanism. Moreover, a similar mechanism likely also accounts for the TNF α detrimering activity of the polyaromatic inhibitor Suramin (23) (Supplementary Figure S2), and for the recently reported inhibition of CD40L by Suramin (25) and other polyaromatic compounds (26), though no structures of the inhibited complexes have yet been obtained in these cases. One difference between the binding modes of BIO8898 and SP307 is that in addition to substantial hydrophobic contact BIO8898 also engages in several hydrogen bonds with the protein. Another important difference is that attempts to dock the missing third subunit of TNF α into the TNF α dimer/SP307 complex indicate that for SP307 to bind to a TNF α trimer in the observed location and conformation requires a much larger distortion of the protein trimer than is seen for CD40L with BIO8898. These differences in binding mode with BIO8898 presumably contribute to stabilization of the intercalated CD40L trimer compared to the protein dimer observed for SP307 with TNF α .

Lessons for Inhibition of PPI by Small Molecules

Our findings for inhibition of CD40L by BIO8898 corroborate several features that have been proposed as important for inhibition of PPI with small molecules. Firstly, as has been observed in other systems (47, 48), a substantial degree of structural adaptivity at the binding site can be necessary to create a binding site for the inhibitor. Second, aromatic residues, and particularly tyrosines, appear to play a privileged role in protein-small

molecule binding, especially at PPI interfaces (49). Aromatic residues, as well as other amino acids such as Arg and Pro that possess planar or partly planar side-chains, are known to be statistically over-represented at PPI interfaces (50-52), and are especially common at energetic hotspots for ligand-receptor binding. Tyrosines in particular are also highly over-represented at the antigen binding regions of antibodies (53). It is noteworthy that BIO8898, SP307, Suramin and several other molecules (Supplementary Figure S2) that are known or believed to inhibit TNF family proteins by trimer disruption all contain extensive polycyclic aromatic and/or biaryl functionality. The notion that aromatic groups are particularly favored in this regard is supported by a statistical analysis of the results of fragment-based screens against multiple targets, a substantial fraction of them protein-protein interactions, that identified biphenyls as a 'privileged' structure for protein binding (54).

If inhibiting transient PPI with small molecules is challenging, finding inhibitors against constitutive, PPIs – which generally have more extensive interfaces and are higher in affinity (9, 10) – might be considered an extreme form of this challenge. The results presented here suggest that this is not always the case, however. Constitutive PPI interfaces are considerably more hydrophobic than their transient counterparts, because the proteins involved do not need to be able to exist stably in monomeric form (9, 10). The activity of BIO8898 against CD40L, and that of SP307 against TNF α , suggests that in some cases this hydrophobicity, coupled with some structural adaptivity of interface residues, can translate into an ability to bind small molecules to form complexes of defined structure. Moreover, because only one of the three interactions in the constitutively trimeric CD40L need be disrupted to allow the inhibitor to bind, an exceptionally deep binding pocket can be created. This contrasts with the rather flat binding sites typically encountered when binding to one partner of a transient PPI. The mechanism observed for BIO8898 might be expected to apply to other constitutive complexes involving three or more protein subunits, potentially providing a means for these conventionally undruggable targets to form a binding site that possesses the characteristics – which are largely topological (55) – required to bind a drug with high affinity.

Three key questions define the potential utility of such an approach for drug discovery. Can molecules of this type be optimized to achieve the low nM potency typically required of a drug? Can the ability of a small molecule to interact with such a site be made compatible with the requirement for acceptable pharmaceutical properties? Can such a molecule achieve adequate selectivity for the target site over hydrophobic sites in other proteins? Existing data do not provide definitive answers to any of these questions. However, with respect to the ability to inhibit TNF family members by trimer disruption the structure of BIO8898 with CD40L is encouraging, in that binding involves a combination of both hydrophobic and polar interactions, whereas the corresponding interactions between SP307 and TNF α were exclusively hydrophobic (12). The BIO8898/CD40L structure therefore demonstrates that it is possible to target such a site with an inhibitor that presents a combination of polar and nonpolar interacting groups, providing increased prospects for selectivity and also for the level of solubility that is a prerequisite for good pharmaceutical properties.

METHODS

Expression and Purification of CD40L

A myc tagged form of soluble human CD40L was constructed with the amino acid sequence:
EQKLISEEDLNMGDQNPQIAAHVISEASSKTTSVLQWAEKGYTMSNNLVTLENGK
QLT
VKRQGLYYIYAQVTFCSNREASSQAPFIASLCLKSPGRFERILLRAANTHSSAKPCGQ
QSI HLGGVFELQPGASVFVNVTDPSSQVSHGTGFTSFGLLKL. The EQKLISEEDL

peptide is the c-myc tag, the adjacent NM residues are an artifact of the cloning strategy, and the CD40L protein sequence begins with residue Gly116. The engineered DNA sequence was cloned into a derivative of the pPIC9 plasmid (Invitrogen) for expression in the yeast *Pichia pastoris* under control of the AOX1 promoter (methanol inducible), fused to the PrePro alpha factor secretion signal of *Saccharomyces cerevisiae*. Plasmid DNA linearized with *Stu*I in the HIS4 region of the plasmid was electroporated into GS115 *Pichia pastoris* following Invitrogen's instructions. Expression of CD40L protein in isolated clones was confirmed by SDS-PAGE and western blotting with anti c-myc monoclonal antibody 9E10. Protein was expressed in Fernbach flasks using 1 L BMGY medium for cell growth at 30 °C followed by 200 mL BMMY (2% (v/v) methanol) medium for induction at 30 °C. Media recipes and growth protocols were according to Invitrogen standard *Pichia* protocols.

The expressed fusion protein was purified by Anion Exchange Chromatography. The buffer exchanged supernatant (20 mM Sodium Phosphate pH 6.5) was passed through a Q Sepharose Fast Flow column (GE Healthcare) and the flow-through was loaded onto an SP sepharose column. After washing the column, the bound protein was eluted using 2X PBS (20 mM sodium phosphate dibasic, 3 mM potassium phosphate monobasic, 5 mM potassium chloride, 260 mM sodium chloride). The protein was > 95% intact based on mass spectrometry. The protein was checked for purity by SDS-PAGE, and was shown to be active by its ability to bind CD40-Ig as measured by Biacore.

Expression and Purification of CD40-Ig

A fusion of the CD40 extracellular domain and the human IgG1 Fc region was expressed using a DNA construct that was a kind gift of from Ellen Garber (Biogen Idec) that encodes the amino acid sequence:

EAMEPPTACREKQYLINSQCCSLCQPGQKLVS DCTEFTETEC LPCGESEFLDTWNRE
 THC
 HQHKYCDPNLGLRVQKGTSETDTICTCEEGWHCTSEACESCVLHRSCSPGFVVKQ
 IAT
 GVSDTICEPCPVGFFSNVSSAFEKCHPWTSCETKDLVVQQAGTNKTDVVC GPQDRL
 RVD
 KTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWY
 VD
 GVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKT
 ISK
 AKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTT
 PPV L DSDGSFFLYSKLTVDKSRWQQGNV FSCSVMHEALHNHYTQKSLSLSPGK.
 The CD40-Ig coding sequence was cloned and expressed in *Pichia pastoris* as described above for myc-CD40L, except that plasmid DNA was digested with *Xba*I prior to electroporation and expression was verified with anti-human IgG1 serum.

CD40-Ig was expressed by fermentation using a modification of Invitrogen Basal Salts medium containing hexametaphosphate (Ryan Ohler, Gary Lesnicki and Michael Galleno, personal communication, Invitrogen Corp). This medium contained, per liter, 9 g ammonium sulfate, 0.93 g CaSO₄·2H₂O, 18.2 g K₂SO₄·7H₂O, 14.9 g MgSO₄·7H₂O, 4.13 g KOH, 9 g NH₄SO₂, 20 g glycerol (all autoclaved), and 25 g sodium hexametaphosphate (Mallinkrodt) added after autoclaving. Ammonium hydroxide was used to maintain pH 6.0 during fermentation, with glycerol feeding to 100 grams/liter wet weight followed by feeding with a mixture of 75% (v/v) methanol + 25% (v/v) glycerol to induce protein production. The expressed fusion protein was captured by Protein-A affinity beads and further purified by Anion Exchange Chromatography. Briefly, the cleared supernatant was dialyzed against PBS (10 mM sodium phosphate dibasic, 1.5 mM potassium phosphate monobasic, 2.5 mM potassium chloride, 130 mM sodium chloride). The buffer exchanged supernatant was then

passed through a Protein-A Sepharose Fast Flow column (GE Healthcare) and the captured protein was eluted with a low pH buffer of 25 mM sodium phosphate pH 2.8. The peak fractions were pooled and dialyzed against 20 mM Tris-HCl pH 7.0, 50 mM NaCl. The dialyzed solution was loaded onto a Q Sepharose Fast Flow (GE Healthcare) column. After washing the column, the bound protein was eluted using a linear sodium chloride gradient from 50-500 mM. Mass spectrometric analysis of the protein indicated two major peaks comprising residues 1-404 and residues 3-404. The protein was checked for purity by SDS-PAGE, and was shown to be active by its ability to bind mycCD40L as measured by Biacore.

Expression and Purification of sCD40. A soluble human CD40 extracellular domain was expressed using a DNA construct that was a kind gift of Ellen Garber (Biogen Idec) that encodes the amino acid sequence:

EAMEPPTACREKQYLINSQCCSLCQPGQKLVSDCTEFTETETCLPCGESEFLDTWNRE
THC

HQHKYCDPNLGLRVQQGTSETDTICTCEEGWHCTSEACESCVLHRSCSPGFGVKQ
IATGVSDTICEPCPVGFFSNVSSAFEKCHPWTSCETKDLVVQQAGTNKTDVVCV.

The shCD40 coding sequence was cloned and expressed in *Pichia pastoris* as described above for CD40-Ig. The protein was purified from media by capturing on Cation Exchange Chromatography and further purification by Size Exclusion Chromatography. Briefly, the cleared supernatant was dialyzed against 25 mM Na-Acetate pH4.0. The dialyzed solution was loaded onto a SP Sepharose Fast Flow (GE Healthcare) column. After washing the column, the bound protein was eluted with 20 mM sodium phosphate pH7.2 with 300 mM sodium chloride. The peak fractions were pooled and concentrated with Centricon concentrator (Millipore). The concentrated solution was then loaded onto a Superdex 75 Size Exclusion (GE Healthcare) column and eluted with PBS (10 mM sodium phosphate dibasic, 1.5 mM potassium phosphate monobasic, 2.5 mM potassium chloride, 130 mM sodium chloride). Mass spectrometric analysis of the protein indicated two major peaks comprising residues 1-170 and residues 3-170. The protein was monomeric as assessed by light scattering, displaying a single peak with apparent molecular weight of 22.7 kDa, and was shown to be active by its ability to bind mycCD40L as measured by Biacore.

Synthesis of BIO8898

BIO8898 was prepared according to the method of Rebek and co-workers (56), as described in WO2002018540 (A2,A3) (29) (Supplementary Figure 1). Details are as follows:

(S)-N-(biphenyl-3-ylmethyl)-4-bromo-6-(2-(pyrrolidin-1-ylmethyl)pyrrolidine-1-carbonyl)picolinamide (2)—4-Bromo-2,6-pyridinedicarboxylic acid (**1**, 1.31 g, 5.33 mmol) was suspended in anhydrous dichloromethane (50 mL) and stirred at room temperature under nitrogen atmosphere as oxalyl chloride (1.92 mL, 21.9 mmol) was added dropwise and followed by one drop of dimethylformamide. The reaction mixture was stirred for 16 h and the solvents were evaporated off. Toluene (10 mL) was added and evaporated off to give the acid chloride as a pale solid. The resulted acid chloride was then dissolved in anhydrous dichloromethane (32 mL) and added to a stirring solution of (S)-(+)-1-(2-pyrrolidinylmethyl)pyrrolidine (0.902 g, 5.86 mmol), 3-phenylbenzylamine (1.07 g, 5.86 mmol), and triethylamine (4.8 mL) in anhydrous dichloromethane (40 mL) at 0 °C under nitrogen. The reaction was allowed to warm to room temperature overnight. The reaction mixture was then concentrated by rotavap, and the residue was purified by flash column chromatography on silica to give the desired product as a white solid (0.91g, 31% yield).

(S)-tert-butyl 2-(4-bromo-6-((S)-2-(pyrrolidin-1-ylmethyl)pyrrolidine-1-carbonyl)picolinamido)-2-cyclohexylacetate (3)—Compound **3** (Supplementary Figure 1) was prepared in a similar manner to compound **2** but starting with 4-Bromo-2,6-

pyridinedicarboxylic acid, (S)-(+)-1-(2-pyrrolidinylmethyl)-pyrrolidine, and (S)-tert-butyl 2-amino-2-cyclohexylacetate.

(S)-tert-butyl 2-(2'-(biphenyl-3-ylmethylcarbamoyl)-6,6'-bis((S)-2-(pyrrolidin-1-ylmethyl)-pyrrolidine-1-carbonyl)-4,4'-bipyridine-2-carboxamido)-2-cyclohexylacetate (4)—[1,1'-

bis(diphenylphosphino)ferrocene]dichloropalladium(II) (complex with CH₂Cl₂) (9 mg, 0.011 mmol) was added to a mixture of (S)-N-(biphenyl-3-ylmethyl)-4-bromo-6-(2-(pyrrolidin-1-ylmethyl)pyrrolidine-1-carbonyl)picolinamide (**2**) (200 mg, 0.366 mmol), bis(pinacolato)diboron (102 mg, 0.402 mmol), and potassium acetate (108 mg, 1.102 mmol) in anhydrous dimethylformamide (2.5 mL). The mixture was heated at 80 °C under nitrogen for 3 h. Another portion of the palladium catalyst (9 mg) and bis(pinacolato)diboron (103 mg, 0.402 mmol) were added and the mixture heated until LC-MS showed the major formation of the desired product. The reaction was allowed to cool to room temperature, and the following were added: (S)-tert-butyl 2-(4-bromo-6-((S)-2-(pyrrolidin-1-ylmethyl)pyrrolidine-1-carbonyl)picolinamido)-2-cyclohexylacetate (**3**) (212 mg, 0.367 mmol), sodium carbonate (194 mg, 1.83 mmol), and water (1 mL). The resulting mixture was heated at 90 °C under nitrogen for 5 h. It was then cooled to room temperature and diluted with diethyl ether (10 mL) and water (10 mL). The aqueous layer was extracted with additional diethyl ether (10 mL). A small amount of precipitate was dissolved in dichloromethane and then combined with the diethyl ether extracts, which were then purified by a silica flash column (20 g) using dichloromethane/methanol/aqueous ammonia (99:1:0.1 to 93:7:0.7) as eluent.

(S)-2-(2'-(biphenyl-3-ylmethylcarbamoyl)-6,6'-bis((S)-2-(pyrrolidin-1-ylmethyl)pyrrolidine-1-carbonyl)-4,4'-bipyridine-2-carboxamido)-2-cyclohexylacetic acid (BIO8898)—(S)-tert-butyl 2-(2'-(biphenyl-3-

ylmethylcarbamoyl)-6,6'-bis((S)-2-(pyrrolidin-1-ylmethyl)-pyrrolidine-1-carbonyl)-4,4'-bipyridine-2-carboxamido)-2-cyclohexylacetate (**4**) (80 mg) was dissolved in dichloromethane (0.1 mL) and trifluoroacetic acid (0.9 mL) was added. The reaction was stirred at room temperature overnight. The solvents were evaporated off and trituration with diethyl ether (10 mL) gave an off-white solid that was further purified by HPLC with 5-95% 0.1% TFA/acetonitrile and water to give the desired product as a white solid. MS/MH⁺: 910.32 and 455.57; ¹H NMR (300 MHz, DMSO-*d*₆) δ ppm 0.96 - 1.32 (m, 6 H) 1.69 - 1.80 (m, 6 H) 1.78 - 2.22 (m, 14 H) 2.54 (s, 1 H) 3.18 (br. s., 3 H) 3.27 - 3.43 (m, 2 H) 3.44 - 3.61 (m, 2 H) 3.63 - 3.93 (m, 6 H) 4.0 - 4.64 (m, 8 H) 4.67 (d, J=6.41 Hz, 2 H) 7.36 (dd, J=7.16, 5.30 Hz, 1 H) 7.45 (dd, J=15.45, 7.80 Hz, 2 H) 7.56 (d, J=7.2 Hz, 1 H) 7.62 (d J=7.62, 2 H) 7.71 (d J=15.1, 1 H) 8.39 (d, J=1.13 Hz, 1 H) 8.42 - 8.50 (m, 2 H) 8.50 - 8.57 (m, 1 H) 8.54 (dd, J=5.27, 1.5 Hz, 1 H) 8.60 - 8.78 (m, 1 H) 9.30 (t, J=6.03 Hz, 1 H) 9.54 - 9.60 (m, 1 H) 9.78 - 9.97 (m, 1 H).

Crystallization and structure determination

BIO8898 was incubated at room temperature for 1 hour with 8 mg/ml CD40L trimer at 1 mM concentrations in the presence of 2% (v/v) DMSO. Needle-like crystals of the CD40L complexed to BIO8898 (Table 1) were initially identified in hanging drop vapor diffusion setups under a 1:1 volume ratio of complex and a crystallization condition consisting of 24% (v/v) Peg3350, 50 mM Hepes pH 7.5, 0.2 M sodium citrate at 20 °C. In optimization efforts, the best plate-like crystals appeared from hanging drops using a 1:1 ratio of protein to a crystallization condition consisting of 25% Peg 3350, 0.1 M sodium cacodylate pH 6.5, 0.2 M ammonium acetate, and 5% (v/v) glycerol. No crystals were observed in parallel drops without BIO8898. The fragile crystals were frozen directly from mother liquor into liquid nitrogen.

Native data was collected from a single crystal frozen at -180°C at beamline X25 at the National Synchrotron Light Source (Upton, NY) with X-rays at a $1.1\text{ \AA}$ wavelength (Table 1). Data processing to $2.5\text{ \AA}$ was carried out with the HKL data package version 1.97.2 (57). The crystals belong to space group $P2_12_12_1$ with unit cell dimensions $a = 63.3\text{ \AA}$, $b = 67.6\text{ \AA}$, $c = 108.5\text{ \AA}$, $\alpha = \beta = \gamma = 90^{\circ}$, which are consistent with a single CD40L trimer per asymmetric unit (Table 1). The structure was solved by molecular replacement with the program AMORE (58) using the CD40L trimer as a search model and using a subset of data to $3.0\text{ \AA}$ resolution. The resultant R_{free} was 55% and correlation coefficient was 29.2. By using a 3-body rigid-body refinement protocol in CNX (59), in which each of the three monomers of the CD40L trimer were treated as a rigid body, the R_{free} dropped to 47% using the subset of data to $3.0\text{ \AA}$. An Fo-Fc difference map showed clear density for a small molecule in the center of the trimer. Refinement was carried out in CNX using an mlf target and reserving 5% of the reflections for the test set to $2.5\text{ \AA}$ native data and was further refined in Refmac5 (60). The final model has an R-factor of 22.6% and an R_{free} of 29.8% and consists of residues 122-178, 183-261 (chain A), 121-131, 135-180, 187-261 (chain B), 121-261 (chain C), one BIO8898, 3 glycan chains, and 77 waters. Ramachandran plots (61) indicate that 0 % of the model is in disallowed regions and 0% in generously allowed regions.

CD40L/CD40-Ig Dissociation Enhanced Lanthanide Fluorescence Immunoassay (DELFI A)

Microtiter plates (Nunc Maxisorp) were coated overnight with $100\text{ }\mu\text{l}$ CD40-Ig at $5\text{ }\mu\text{g/ml}$ in PBS, pH 7.2 at 4°C , washed three times with PBS containing 0.05% (v/v) Tween (PBS-T), and blocked for 1 hour with Superblock in PBS ($200\text{ }\mu\text{l}$, Pierce) at room temperature. Compounds were serially diluted 3-fold in DMSO ($0.025\text{--}500\text{ }\mu\text{M}$) added to the plate along with $0.04\text{ }\mu\text{g/ml}$ myc-CD40L in assay buffer (2% (v/v) Superblock, PBS, pH 7.4, final volume $100\text{ }\mu\text{l}$). The reaction contained 1% DMSO final and was incubated for 1 hour at room temperature, washed three times with PBS-T, and binding was detected by the addition of $100\text{ }\mu\text{l}$ of a $29\text{ }\mu\text{g/ml}$ solution of Europium-Anti-myc (Perkin Elmer) in DELFIA assay buffer (Perkin Elmer) for 1 hour at room temperature. The wells were washed 8 times with PBS-T, $100\text{ }\mu\text{l}$ of DELFIA enhancement solution (Perkin Elmer) was added, and the plate was mixed for 5 minutes at room temperature. Time-resolved fluorimetry measurements were made using an Analyst plate reader (Molecular Devices), and the percent activity at a given compound concentration was calculated using the following equation: % activity = $100 \times (\text{signal with compound}/\text{signal without compound})$ which was used to generate IC₅₀ curves. The data was generated in triplicate and averaged with error bars shown. Data were fitted to a hyperbolic inhibition equation with a non-zero offset: $\text{Activity} = A_{\text{max}} - \{(A_{\text{max}} - A_{\text{min}})[\text{BIO8898}]/(\text{IC}_{50} + [\text{BIO8898}])\}$, where A_{max} and A_{min} represents maximum and minimum % activity (i.e. activity at zero [BIO8898] and saturating [BIO8898], respectively), and IC₅₀ represents the concentration of BIO8898 giving 50% inhibition (i.e. giving %A = $(A_{\text{max}} - A_{\text{min}})/2 + A_{\text{min}}$).

CD40L mediated apoptosis assay

MTT (3-[4,5-Dimethylthiazol-2-yl]-2,5-diphenyl-tetrazolium bromide) (Sigma M-2128) and cyclohexamide (CHX; Sigma, C-7698) were purchased from Sigma-Aldrich Corp. Baby hamster kidney (BHK) cells, stably transfected with a chimeric receptor containing the extracellular domain of human CD40 and the intracellular domain of human TNFR1 (CD40-TNFR-BHK), were kindly provided by Dr. Hartmut Engelmann, University of Munich, Germany, and were grown in RPMI medium containing 10% (v/v) heat-inhibited fetal bovine serum, 2 mM L-Glutamine, 50 U ml^{-1} Penicillin/Streptomycin, and $600\text{ }\mu\text{g ml}^{-1}$ G418.

CD40-TNFR-BHK cells were cultured with a density of 5×10^4 cells per well in 96-well plate. A stock solution of BIO8898 in DMSO was serially diluted in culture medium, pre-mixed with soluble CD40L and CHX to final concentrations of 3 ng ml^{-1} and 50 g ml^{-1} , respectively, and added to the cultures in 96-well plates. On the third day, 10 l of MTT (5 mg/ml in PBS) was added to each well and the plates were incubated for 4 hours, followed by addition of 100 l 10% SDS/0.01 N HCl, and a further incubation overnight at 37°C . The number of viable cells in each well was assessed by measuring the optical absorbance at 590 nm for each well. Data were fitted using a hyperbolic equation: $A_{590} = A_{590}(\text{min}) + \{(A_{590}(\text{max}) - A_{590}(\text{min}))([\text{BIO8898}]/\text{EC}_{50} + [\text{BIO8898}])\}$, where $A_{590}(\text{max})$ and $A_{590}(\text{min})$ represent the minimum and maximum absorbance values, and EC_{50} represents the concentration of BIO8898 that gave an A_{590} value half way between $A_{590}(\text{min})$ and the extrapolated value for $A_{590}(\text{max})$. The data in Figure 1C do not approach saturation because the maximum concentration of BIO8898 that could be used in the assay was limited by its low solubility and the low tolerance of the assay for DMSO. Nevertheless, data were obtained up to a concentration of BIO8898 of 111 M, which exceeds the fitted EC_{50} value of $\sim 69 \text{ M}$, suggesting that this value reflects a valid if approximate estimate of the potency of BIO8898 in this assay.

CD40L Trimer Disruption Assay

The ability of BIO8898 to cause the dissociation of the CD40L trimer was measured using an assay analogous to that established for the TNF α trimer disruptor SP307 (12). Briefly, sparsely biotinylated CD40L designed to possess no more than one biotin molecule per trimer was prepared by reacting 10 molar equivalents of CD40L Q186C mutant (calculated based on the monomer) with 1 equivalent of Sulfo-NHS-LC-biotin (Pierce) in 50 mM sodium carbonate, pH 9.0 with 150 mM NaCl for 60 minutes at room temperature. The reaction was quenched with 10 mM ethanolamine and purified by gel filtration. The singly-biotinylated CD40L was captured on neutravidin-coated assay plates, and then incubated with BIO8898 at various concentrations or with assay buffer alone containing 1% (v/v) DMSO. The ability of the captured CD40L to bind CD40-Ig was measured either with or without a prior wash step to remove any dissociated CD40L subunits. If trimer dissociation occurs the dissociated subunits would be expected to recombine with each other in solution and then become lost upon washing, resulting in a loss of active CD40L from the assay plate and a reduction in the binding of CD40-Ig. The data shown are the results of a single experiment.

Biacore Binding Measurements

All experiments were performed using a Biacore 3000 instrument (GE Healthcare).

Biacore chip surface preparation

CD40-Ig was immobilized on CM5 sensorchips (GE Healthcare) using the Biacore Amine Coupling Kit according to the manufacturer's instructions. Briefly, CD40-Ig was diluted to $50 \text{ }\mu\text{g/ml}$ in 10 mM acetate, pH 5.0, and $50 \text{ }\mu\text{l}$ was injected over chip surfaces that had been activated with a $50 \text{ }\mu\text{l}$ injection of 1:1 N-hydroxysuccinimide (NHS): 1-Ethyl-3-(3-dimethylaminopropyl)-carbodiimide hydrochloride (EDC). Remaining activated carboxylate esters on the chip surface were capped by injecting $50 \text{ }\mu\text{l}$ of 1 M ethanolamine over the chip surface. Typical immobilization levels were 4000-6000 RU.

Solution-phase Biacore binding assays

The binding of soluble CD40L to CD40-Ig or sCD40 was measured in solution using the initial rates receptor-ligand Biacore titration method we have described previously (41).

Briefly, CD40L was mixed in various molar ratios with CD40-Ig or sCD40 in HBS buffer (10 mM HEPES pH 7.0, 150 mM NaCl, 3.4 mM EDTA, 0.05% P-20 detergent plus 0.05% BSA) and incubated at 4 °C for a minimum time of 3 hours. This same buffer was used as the running buffer during sample analysis. 50 μ l of each pre-equilibrated solution was then injected at 5 μ l min⁻¹ over a CD40-Ig derivatized surface, or over an adjacent, underivatized surface as a background control, followed by a 3 minute dissociation in HBS buffer. Following each reaction cycle the Biacore chip surface was regenerated with 2 $\times$ 20 μ l injections of 2M Guanidine-HCL + 0.5 M KCl. Under these experimental conditions the binding is mass transport limited during approximately the first minute of binding. The mass transport limited region of the sensorgrams was determined from the region where the slope of a first derivative plot of dRU/dt was zero. During the mass transport limited binding phase the initial rate of binding (V_i) is proportional to the concentration of free ligand in solution (42). As only free CD40L is able to bind to the CD40-Ig surface, V_i therefore acts as a measure of the concentration of free CD40L in each solution (41). A plot of the initial rate of binding (V_i) measured at various concentrations of CD40L alone was fitted to a straight line to give a standard curve that was used to convert V_i values to [CD40L]_{free} values for subsequent measurements. The binding affinity was determined by plotting [CD40L]_{free} versus [CD40-Ig]_{total} and fitting the data to the following quadratic binding equation:

$$[L]_f = \left[[L]_T - \frac{1}{2} \left\{ \left(n[R]_T + [L]_T + K_D \right) - \sqrt{\left(n[R]_T + [L]_T + K_D \right)^2 - 4n[R]_T[L]_T} \right\} \right]$$

where $[L]_f$ (i.e. the y axis variable) equals the concentration of free CD40L present in a given solution; $[L]_T$ is the total CD40L concentration present in each sample; $[R]_T$ is the total CD40-Ig concentration present in the solutions; n is the stoichiometry of CD40-Ig binding to CD40L; and K_D is the binding affinity. The affinity of the monomeric sCD40 binding to CD40L was determined using the same method by preincubating a fixed concentration of CD40L with various concentrations of sCD40, determining [CD40L]_{free} for each sample at equilibrium as described above, and then plotting [CD40L]_{free} versus [sCD40]_{total} and fitting the data to hyperbolic binding equation: $[L]_f = [L]_T - [L]_T \{ [R]_T / (K_D + [R]_T) \}$, where $[L]_f$, $[L]_T$, $[R]_T$ and K_D have the definitions given above. The interaction was sufficiently weak that no stoichiometry information is contained in the data. A hyperbolic curve fit was appropriate for the weak binding of sCD40 because the experiment was performed under conditions where the concentration of the fixed component, CD40L, was low compared to K_D ; for the experiment with CD40-Ig the fixed component was present at a concentration that was high compared to K_D , necessitating the use of a quadratic binding equation (41).

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

The authors would like to acknowledge P.A. Boriack-Sjodin for aid in data collection and A. Saxena for access to X25 beamtime at the NSLS.

References

1. Wells JA, McClendon CL. Reaching for high-hanging fruit in drug discovery at protein-protein interfaces. *Nature*. 2007; 450:1001–1009. [PubMed: 18075579]

2. Gerrard JA, Hutton CA, Perugini MA. Inhibiting protein-protein interactions as an emerging paradigm for drug discovery. *Mini Rev Med Chem*. 2007; 7:151–157. [PubMed: 17305589]
3. Fischer P. Protein-Protein Interactions in Drug Discovery. *Drug Design Reviews -Online*. 2005; 2:179–207.
4. Whitty A, Kumaravel G. Between a rock and a hard place? *Nat Chem Biol*. 2006; 2:112–118. [PubMed: 16484997]
5. Ganesan A. The impact of natural products upon modern drug discovery. *Curr Opin Chem Biol*. 2008; 12:306–317. [PubMed: 18423384]
6. Vu BT, Vassilev LT. Small-Molecule Inhibitors of the p53-MDM2 Interaction. *Curr Top Microbiol Immunol*. 2010 2010/11/04.
7. Dynek JN, Vucic D. Antagonists of IAP proteins as cancer therapeutics. *Cancer Lett*. 2010 2010/08/06.
8. Wilson WH, O'Connor OA, Czuczman MS, LaCasce AS, Gerecitano JF, Leonard JP, Tulpule A, Dunleavy K, Xiong H, Chiu YL, Cui Y, Busman T, Elmore SW, Rosenberg SH, Krivoshik AP, Enschede SH, Humerickhouse RA. Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase I dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. *Lancet Oncol*. 2010; 11:1149–1159. [PubMed: 21094089]
9. Headd JJ, Ban YE, Brown P, Edelsbrunner H, Vaidya M, Rudolph J. Protein-protein interfaces: properties, preferences, and projections. *J Proteome Res*. 2007; 6:2576–2586. [PubMed: 17542628]
10. Nooren IM, Thornton JM. Structural characterisation and functional significance of transient protein-protein interactions. *J Mol Biol*. 2003; 325:991–1018. [PubMed: 12527304]
11. Bannwarth L, Reboud-Ravax M. An alternative strategy for inhibiting multidrug-resistant mutants of the dimeric HIV-1 protease by targeting the subunit interface. *Biochem. Soc. Trans*. 2007; 35:551–554. [PubMed: 17511649]
12. He MM, Smith AS, Oslob JD, Flanagan WM, Braisted AC, Whitty A, Cancilla MT, Wang J, Lugovskoy AA, Yoburn JC, Fung AD, Farrington G, Eldredge JK, Day ES, Cruz LA, Cachero TG, Miller SK, Friedman JE, Choong IC, Cunningham BC. Small-molecule inhibition of TNF- α . *Science*. 2005; 310:1022–1025. [PubMed: 16284179]
13. Schonbeck U, Libby P. The CD40/CD154 receptor/ligand dyad. *Cell Mol Life Sci*. 2001; 58:4–43. [PubMed: 11229815]
14. Daikh DI, Finck BK, Linsley PS, Hollenbough D, Wofsy D. Long-term inhibition of murine lupus by brief simultaneous blockade of the B7/CD28 and CD40/gp39 costimulation pathways. *J. Immunol*. 1997; 159:3104–3108. [PubMed: 9317105]
15. Cho CS, Burkly LC, Fechner JH Jr, Kirk AD, Oberley TD, Dong Y, Brunner KG, Peters D, Tenhoo CN, Nadeou K, Yagci G, Ishido N, Schultz JM, Tsuchida M, Hamawy MM, Knechtle SJ. Successful conversion from conventional immunosuppression to anti-CD40L monoclonal antibody costimulatory molecule blockade in rhesus renal allograft recipients. *Transplantation*. 2001; 72:587–597. [PubMed: 11544416]
16. Sho M, Sandner SE, Najafian N, Salama AD, Dong V, Yamada A, Kishimoto K, Haraa H, Schmitt I, Sayegh MH. New insights into the interactions between T-cell costimulatory blockade and conventional immunosuppressive drugs. *Ann. Surg*. 2002; 236:667–675. [PubMed: 12409674]
17. Schonbeck U, Libby P. CD40 signaling and plaque instability. *Circ Res*. 2001; 89:1092–1103. [PubMed: 11739273]
18. Karpusas M, Lucci J, Ferrant J, Benjamin C, Taylor FR, Strauch K, Garber E, Hsu YM. Structure of CD40 ligand in complex with the Fab fragment of a neutralizing humanized antibody. *Structure*. 2001; 9:321–329. [PubMed: 11525169]
19. Singh J, G. E, Van Vlijmen H, Karpusas M, Hsu YM, Zheng Z, Naismith JH, Thomas D. The role of polar interactions in the molecular recognition of CD40L with its receptor CD40. *Protein Sci*. 1998; 7:1124–1135. [PubMed: 9605317]
20. Boumpas DT, Furie R, Manzi S, Illei GG, Wallace DJ, Balow JE, Vaishnaw A. A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis. *Arthritis Rheum*. 2003; 48:719–727. [PubMed: 12632425]

21. Ferrant JL, Benjamin CD, Cutler AH, Kalled SL, Hsu Y-M, Garber EA, Hess DM, Shapiro RI, Kenyon NS, Harlan DM, Kirk AD, Burkly LC, Taylor FR. The contribution of Fc effector mechanisms in the efficacy of anti-CD154 immunotherapy depends on the nature of the immune challenge. *International Immunology*. 2004; 16:1583–1594. [PubMed: 15466914]
22. Voogd TE, Vansterkenburg EL, Wilting J, Janssen LH. Recent research on the biological activity of suramin. *Pharmacol Rev*. 1993; 45:177–203. [PubMed: 8396782]
23. Alzani R, Corti A, Grazioli L, Cozzi E, Ghezzi P, Marcucci F. Suramin induces deoligomerization of human tumor necrosis factor alpha. *J Biol Chem*. 1993; 268:12526–12529. [PubMed: 8509393]
24. Grazioli L, Alzani R, Ciomei M, Mariani M, Restivo A, Cozzi E, Marcucci F. Inhibitory effect of suramin on receptor binding and cytotoxic activity of tumor necrosis factor alpha. *Int J Immunopharmacol*. 1992; 14:637–642. [PubMed: 1325955]
25. Margolles-Clark E, Jacques-Silva MC, Ganesan L, Umland O, Kenyon NS, Ricordi C, Berggren PO, Buchwald P. Suramin inhibits the CD40-CD154 costimulatory interaction: a possible mechanism for immunosuppressive effects. *Biochem Pharmacol*. 2009; 77:1236–1245. [PubMed: 19283894]
26. Margolles-Clark E, Umland O, Kenyon NS, Ricordi C, Buchwald P. Small-molecule costimulatory blockade: organic dye inhibitors of the CD40-CD154 interaction. *J Mol Med*. 2009; 87:1133–1143. [PubMed: 19707732]
27. Margolles-Clark E, Kenyon NS, Ricordi C, Buchwald P. Effective and specific inhibition of the CD40-CD154 costimulatory interaction by a naphthalenesulphonic acid derivative. *Chem Biol Drug Des*. 2010; 76:305–313. [PubMed: 20636329]
28. Ganesan L, Margolles-Clark E, Song Y, Buchwald P. The food colorant erythrosine is a promiscuous protein-protein interaction inhibitor. *Biochem Pharmacol*. 2011; 81:810–818. [PubMed: 21219880]
29. Zheng, Z.; Carter, M-B.; Liao, Y.; Sun, L.; Kirkovsky, L.; Mrose, S.; Hsu, Y.; Thomas, D.; Shipps, GW., Jr.; Jindal, S.; Lenz, GR.; Nash, HM. Novel CD40:CD154 binding interruptor compounds and use thereof to treat immunological complications. C12N. WIPO. , editor. Biogen, Inc.; 2002.
30. Annis DA, Nazef N, Chuang CC, Scott MP, Nash HM. A general technique to rank protein-ligand binding affinities and determine allosteric versus direct binding site competition in compound mixtures. *JACS*. 2004; 126:15495–15503.
31. Jurgens G, Hermann A, Aktuna D, Petek W. Dissociation-enhanced lanthanide fluorescence immunoassay of lipoprotein(a) in serum. *Clin Chem*. 1992; 38:853–859. [PubMed: 1534526]
32. Schwabe RF, Hess S, Johnson JP, Engelmann H. Modulation of soluble CD40 ligand bioactivity with anti-CD40 antibodies. *Hybridoma*. 1997; 16:217–226. [PubMed: 9219031]
33. Plumb JA. Cell sensitivity assays: the MTT assay. *Methods Mol Med*. 2004; 88:165–169. [PubMed: 14634227]
34. Coan KE, Shoichet BK. Stoichiometry and physical chemistry of promiscuous aggregate-based inhibitors. *JACS*. 2008; 130:9606–9612.
35. Feng BY, Simeonov A, Jadhav A, Babaoglu K, Inglese J, Shoichet BK, Austin CP. A high-throughput screen for aggregation-based inhibition in a large compound library. *J Med Chem*. 2007; 50:2385–2390. [PubMed: 17447748]
36. Karpusas M, Hsu YM, Wang JH, Thompson J, Lederman S, Chess L, Thomas D. 2 A crystal structure of an extracellular fragment of human CD40 ligand. *Structure*. 1995; 3:1426. [PubMed: 8747468]
37. Reynolds C, Damerell D, Jones S. ProtorP: a protein-protein interaction analysis server. *Bioinformatics*. 2009; 25:413–414. [PubMed: 19001476]
38. Braisted AC, Oslob JD, Delano WL, Hyde J, McDowell RS, Waal N, Yu C, Arkin MR, Raimundo BC. Discovery of a potent small molecule IL-2 inhibitor through fragment assembly. *JACS*. 2003; 125:3714–3715.
39. Fournel S, Wieckowski S, Sun W, Trouche N, Dumortier H, Bianco A, Chaloin O, Habib M, Peter JC, Schneider P, Vray B, Toes RE, Offringa R, Melief CJ, Hoebeke J, Guichard G. C3-symmetric peptide scaffolds are functional mimetics of trimeric CD40L. *Nat. Chem. Biol*. 2005; 1:377–382. [PubMed: 16370373]

40. Bajorath J, Chalupny NJ, Marken JS, Siadak AW, Skonier J, Gordon M, Hollenbaugh D, Noelle RJ, Ochs HD, Aruffo A. Identification of residues on CD40 and its ligand which are critical for the receptor-ligand interaction. *Biochemistry*. 1995; 34:1833–1844. [PubMed: 7531493]
41. Day ES, Cachero TG, Qian F, Sun Y, Wen D, Pelletier M, Hsu YM, Whitty A. Selectivity of BAFF/BLyS and APRIL for binding to the TNF family receptors BAFFR/BR3 and BCMA. *Biochemistry*. 2005; 44:1919–1931. [PubMed: 15697217]
42. BIAtchnology Handbook. Biacore AB; 1998. p. 6-5.
43. Holler N, Kataoka T, Bodmer JL, Romero P, Romero J, Deperthes D, Engel J, Tschopp J, Schneider P. Development of improved soluble inhibitors of FasL and CD40L based on oligomerized receptors. *J Immunol Methods*. 2000; 237:159–173. [PubMed: 10725460]
44. He XH, Xu LH, Liu Y. Enhancement of binding activity of soluble human CD40 to CD40 ligand through incorporation of an isoleucine zipper motif. *Acta Pharmacol Sin*. 2006; 27:333–338. [PubMed: 16490170]
45. Van Broekhoven CL, Altin JG. A novel system for convenient detection of low-affinity receptor-ligand interactions: chelator-lipid liposomes engrafted with recombinant CD4 bind to cells expressing MHC class II. *Immunol Cell Biol*. 2001; 79:274–284. [PubMed: 11380681]
46. Hollenbaugh D, Douthwright J, McDonald V, Aruffo A. Cleavable CD40Ig fusion proteins and the binding to sgp39. *J Immunol Methods*. 1995; 188:1–7. [PubMed: 8551028]
47. Brown SP, Hajduk PJ. Effects of conformational dynamics on predicted protein druggability. *ChemMedChem*. 2006; 1:70–72. [PubMed: 16892338]
48. Arkin MR, Randal M, DeLano WL, Hyde J, Luong TN, Oslob JD, Raphael DR, Taylor L, Wang J, McDowell RS, Wells JA, Braisted AC. Binding of small molecules to an adaptive protein-protein interface. *Proc Natl Acad Sci U S A*. 2003; 100:1603–1608. [PubMed: 12582206]
49. Whitty, A. Small-Molecule Inhibitors of Protein-Protein Interactions: Challenges and Prospects. In: Lackey, KE., editor. *Gene Family Targeted Molecular design*. Wiley; Hoboken: 2008. p. 199-226.
50. Bogan AA, Thorn KS. Anatomy of hot spots in protein interfaces. *J Mol Biol*. 1998; 280:1–9. [PubMed: 9653027]
51. Lo Conte L, Chothia C, Janin J. The atomic structure of protein-protein recognition sites. *J Mol Biol*. 1999; 285:2177–2198. [PubMed: 9925793]
52. Glaser F, Steinberg DM, Vakser IA, Ben-Tal N. Residue frequencies and pairing preferences at protein-protein interfaces. *Proteins*. 2001; 43:89–102. [PubMed: 11276079]
53. Koide S, Sidhu SS. The importance of being tyrosine: lessons in molecular recognition from minimalist synthetic binding proteins. *ACS Chem Biol*. 2009; 4:325–334. [PubMed: 19298050]
54. Hajduk PJ, Bures M, Praestgaard J, Fesik SW. Privileged molecules for protein binding identified from NMR-based screening. *J Med Chem*. 2000; 43:3443–3447. [PubMed: 10978192]
55. Nayal M, Honig B. On the nature of cavities on protein surfaces: application to the identification of drug-binding sites. *Proteins*. 2006; 63:892–906. [PubMed: 16477622]
56. Pryor KE, Shippy GW, Skyler DA, Rebek J. The activated core approach to combinatorial chemistry: A selection of new core molecules. *Tetrahedron*. 1998; 54:4107–4124.
57. Otwinowski, Z.; Minor, W. Processing of X-ray diffraction data collected in oscillation mode. In: Carter, CW.; M. S., JR., editors. *Methods in Enzymology*. Academic Press; New York: 1997. p. 307-326.
58. Navaza J. AMoRe: an Automated Package for Molecular Replacement. *Acta Cryst*. 1994; A50:157–163.
59. Brunger AT, Adams PD, Clore GM, DeLano WL, Gros P, Grosse-Kunstleve RW, Jiang J-S, Kuszewski J, Nilges M, Pannu NS, Read RJ, Rice LM, Simonson T, Warren GL. Crystallography & NMR system: A new software suite for macromolecular structure determination. *Acta Crystallogr D Biol Crystallogr*. 1998; 54:905–921. [PubMed: 9757107]
60. Vagin AA, Steiner RA, Lebedev AA, Potterton L, McNicholas S, Long F, Murshudov GN. REFMAC5 dictionary: organization of prior chemical knowledge and guidelines for its use. *Acta Crystallogr D Biol Crystallogr*. 2004; 60:2184–2195. [PubMed: 15572771]
61. Laskowski RA, MacArthur MW, Moss DS, Thornton JM. PROCHECK: a program to check the stereochemical quality of protein structures. *J. Applied Crystallography*. 1993; 26:283–291.

Figure 1.

Structure and activity of BIO8898. a) Chemical structure of BIO8898. b) BIO8898 inhibits the binding of 40 ng/ml mycCD40L to CD40-Ig with $\text{IC}_{50} \sim 25 \mu\text{M}$. CD40-Ig was coated on the assay plate, and the binding of mycCD40L was measured after one hour by DELFIA using a europium-labeled anti-myc antibody, as described in Materials and Methods. Data points are the average of triplicate measurements from a single experiment, with the standard deviation shown by the error bars. The solid line represents the best fit of a hyperbolic (single site) binding equation. c) BIO8898 inhibits the ability of 3 ng/ml mycCD40L plus 50 $\mu\text{g/ml}$ cyclohexamide to induce apoptosis in BHK cells transfected with a chimeric receptor comprising the extracellular domain of CD40 fused to the transmembrane and cytoplasmic domains of the structurally related TNF family receptor TNFR2, or p75. The number of viable cells present after two days was determined by MTT staining, as described in Materials and Methods. The absorbance of control wells containing the same concentration of DMSO but no BIO8898 was subtracted from each measurement. A higher absorbance at 590 nm indicates more live cells. Data are plotted as the average of two independent experiments, with the error bars showing the spread between the values observed in each experiment. Inset plot shows the same data plotted on a linear rather than a logarithmic concentration axis. The BIO8898 dose-response curve does not reach saturation because compound concentrations were limited by poor solubility at the low DMSO levels that the assay can tolerate. The solid line represents the best fit to a hyperbolic binding equation ($\text{EC}_{50} = 69 \mu\text{M}$).

Figure 2.

Structure of BIO8898/CD40L complex. a) Sigma-A weighted omit map density contoured around BIO8898 at 1 sigma. b) Space-filling representation of native CD40L trimer, as viewed from the top in relation to the three-fold axis of symmetry, to compare with BIO8898-bound CD40L: Subunit A (green), Subunit B (magenta), subunit C (tan). c) Side view and (D) top view of the complex of BIO8898 with CD40L. The atoms of the inhibitor are colored as follows: C, yellow; N, blue; O, red. The atoms of the CD40L glycan that were visible in the structure are shown in stick representation (dark blue) and the subunits are colored according to b). e) Closer view of the inhibitor binding region from (C) with protein subunits A and C rendered partially transparent to better show the orientation of the bound compound and the extent to which it is buried within the protein. f) Closer view of the inhibitor binding region, with CD40L subunits shown in ribbon representation to illustrate the binding locations of the four arms of the bound BIO8898.

Figure 3.

Details of the intermolecular interactions between BIO8898 and CD40L. a) Hydrogen bonding interactions connecting protein, ligand, and ordered water molecules in the binding site. b) Ribbons representation of the rigid-body conformational changes of CD40L bound to BIO8898 (colored by subunits) when superimposed with subunit B of unbound CD40L (grey). c) Residues Tyr170 and His224 (shown in space-filling representation) contributed by each of the three CD40L subunits form a compact core in the native trimer. Subunit A has been removed from the representation, except for residues Y170 and H224 (shown in pale brown), to allow a clearer view of the core interactions. d) Same view as in c) but for the BIO8898/CD40L complex showing how Tyr170 and His224 conformationally adapt to accommodate the inhibitor. e) The AA'' loop of subunit A undergoes a substantial conformational change from its position in the native trimer (shown in grey) to the position it occupies in the complex with BIO8898 (shown in pale brown) in which it covers the compound (yellow stick).

Figure 4.

Comparison of BIO8898/CD40L complex to the SP307/TNFα complex reported in He et al. a) Structure of inhibitor SP307 (12). b) Superposition of backbone C-alphas of SP307/TNFα complex (grey) and the BIO8898/CD40L (yellow), with CD40L subunit A removed for clarity, illustrating that the SP307 and Arm 4 of BIO8898 bind in corresponding locations in the core of the protein. The N-termini of the protein are at the bottom of the figure and is thus reversed from the orientation shown in Figure 3.c) Similar side-chains are involved in binding SP307 to TNFα (grey with black labels) and BIO8898 to CD40L (yellow with blue labels), including many conserved aromatic residues. d) Structure-based sequence alignment of CD40L with other TNF-family members illustrating conservation in residues contacting BIO8898. In particular, residues 170, 172 and 224, which are exploited for BIO8898 interactions in more than 1 subunit, and are highly homologous across several family TNF members. Color coding is as follows: dark blue, exact identity with CD40L; light blue, similar aromatic or hydrophobic side-chains to those in CD40L. e) Mechanism proposed by He et al., for the inhibition of TNFα by SP307, in which *T* represents the intact trimeric cytokine and *C2* represents the complex of inhibitor with dimeric cytokine that was observed for TNFα with SP307. The species *C1* corresponds to a complex in which the inhibitor is intercalated into the protein trimer, as we report here for CD40L with BIO8898.

Figure 5.

Dissociation and stoichiometry assays. a) BIO8898 dose-dependently inhibits the binding of CD40-Ig to sparsely biotinylated CD40L that has been captured via a single biotin per trimer on a neutravidin-coated assay plate (black bars). However, if the assay plate is washed prior to CD40-Ig addition, to remove compound plus any dissociated CD40L subunits, no inhibition is observed (grey bars), showing that binding of BIO8898 does not cause irreversible disruption of CD40L or full ejection of CD40L subunits from the complex. The results shown are from a single experiment. b) Binding of mycCD40L to CD40-Ig in solution, as measured using the initial rates Biacore titration method. Pre-incubation of individual samples each containing 100 nM CD40L with the indicated concentrations of CD40-Ig results in detection of lower concentrations of free CD40L, as the CD40L molecules that are bound by CD40-Ig in solution at equilibrium are blocked from binding to the CD40-Ig on the Biacore chip and thus are not detected. The solid line represents the best fit of the CD40L/CD40-Ig data to a quadratic binding equation, giving an apparent K_D for this interaction of 7.6 ± 2.1 nM ($n = 13$). c) Similar experiment to that shown in (b), except that samples containing fixed concentrations of 1.5 M CD40L were pre-incubated with 0–24 M monomeric sCD40 before each mixture was analyzed by Biacore. The data represent the mean of two Biacore measurements of each solution, separated by several hours. Error bars showing the spread of the duplicate data points are included, but in most cases are smaller than the data symbol so cannot be seen. The solid line represents the best fit to a hyperbolic binding equation, indicating that CD40L binds monomeric sCD40 in solution only weakly, with $K_D = 13 \pm 2$ M ($n = 2$).

Table 1

X-Ray Data Collection and Refinement Statistics

PROPERTY	VALUE
Space group	P2 ₁ 2 ₁ 2 ₁
Cell dimensions	
<i>a</i> , <i>b</i> , <i>c</i> (Å)	63.3, 67.6, 108.5
α , β , γ (°)	90.0, 90.0, 90.0
Resolution (Å)	50-2.5 (2.59-2.50) ^a
<i>R</i> _{merge}	0.050 (0.157)
<i>I</i> / σ <i>I</i>	30.7 (5.8)
Completeness (%)	98.5 (92.5)
Redundancy	3.98 (3.20)
Refinement	
Resolution (Å)	20-2.5
No. reflections	15,594
<i>R</i> _{work} / <i>R</i> _{free}	22.6(29.8)
No. atoms	
Protein	2997
Ligand	67
Sugars	117
Water	73
B-factors (Å²)	
Wilson B	58.4
Protein	37.1
Ligand	32.8
Sugars	67.8
Water	40.9
R.m.s deviations	
Bond lengths (Å)	0.017
Bond angles (°)	1.91

^aData collected on single crystal. Highest resolution shell is shown in parenthesis.